Dysautonomia: a common comorbidity of systemic disease
- PMID: 40624434
- PMCID: PMC12234583
- DOI: 10.1007/s12026-025-09661-2
Dysautonomia: a common comorbidity of systemic disease
Abstract
Referring to a broad spectrum of the autonomic symptoms, autonomic disorders, and general dysfunction of the autonomic nervous system, dysautonomia is one of the common and under-recognized comorbidities of a wide variety of systemic disease, including diabetes, autoimmune disorders, vitamin deficiencies, and hormonal dysregulation. The most common autonomic disorders encountered in clinical practice are postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope (NCS), and orthostatic hypotension (OH), which may be undiagnosed or often mislabeled with psychiatric disorders. Typical clinical features of dysautonomia, such as orthostatic dizziness/lightheadedness, orthostatic intolerance, palpitations, exercise intolerance, cognitive dysfunction, and fatigue, should prompt a diagnostic investigation for dysautonomia, which includes an in-office 10-min stand test or a tilt table test in conjunction with other autonomic function tests if available. Treatment approach consists of non-pharmacologic and pharmacologic therapies with beta blockers, midodrine, ivabradine, pyridostigmine, fludrocortisone, stimulants, and other medications. In clinical setting, dysautonomia may present a diagnostic and therapeutic challenge in patients with various systemic disorders and may require a high index of suspicion on the part of the clinician. Importantly, diagnosing and treating dysautonomia is critical to providing comprehensive and personalized medical care to complex patients with chronic illness, who are typically highly symptomatic with multi-systemic complaints as a result of comorbid, and often undiagnosed, dysautonomia.
Keywords: Autonomic dysfunction; Dysautonomia; Neurocardiogenic syncope (NCS); Orthostatic hypotension (OH); Postural orthostatic tachycardia syndrome (POTS).
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: None required for this review. Consent for publication: Not applicable. Competing interests: SB serves on the Executive Committee for CSL Behring. SB serves as a non-paid member on the NIH RECOVER-TLC Neurological Agents Committee.
Similar articles
-
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.Clin Gastroenterol Hepatol. 2025 Jul;23(8):1291-1302. doi: 10.1016/j.cgh.2025.02.015. Epub 2025 May 19. Clin Gastroenterol Hepatol. 2025. PMID: 40387691 Review.
-
Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities.Curr Neurol Neurosci Rep. 2023 Nov;23(11):769-776. doi: 10.1007/s11910-023-01307-w. Epub 2023 Oct 17. Curr Neurol Neurosci Rep. 2023. PMID: 37847487 Review.
-
Dysautonomia: A Forgotten Condition - Part 1.Arq Bras Cardiol. 2021 Apr;116(4):814-835. doi: 10.36660/abc.20200420. Arq Bras Cardiol. 2021. PMID: 33886735 Free PMC article. English, Portuguese.
-
Colour changes in the feet: a sign of autonomic symptoms in systemic sclerosis.Rheumatology (Oxford). 2025 May 1;64(5):3080-3084. doi: 10.1093/rheumatology/keae516. Rheumatology (Oxford). 2025. PMID: 39302703
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
References
-
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72. 10.1007/s10286-011-0119-5. - PubMed
-
- Benarroch EE. “Dysautonomia”: a plea for precision. Clin Auton Res. 2021;31(1):27–9. 10.1007/s10286-020-00749-3. - PubMed
-
- Ståhlberg M, Mahdi A, Johansson M, Fedorowski A, Olshansky B. Cardiovascular dysautonomia in postacute sequelae of SARS-CoV-2 infection. J Cardiovasc Electrophysiol. 2024;35(3):608–17. 10.1111/jce.16117. - PubMed
-
- Blitshteyn S. Dysautonomia, hypermobility spectrum disorders and mast cell activation syndrome as migraine comorbidities. Curr Neurol Neurosci Rep. 2023;23:769–76. 10.1007/s11910-023-01307-w. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources